Showing 14 of 14 results

Organisation Mondiale de la Santé (OMS)
Cette note de synthèse actualisée sur les vaccins contre l’encéphalite japonaise (EJ) remplace la note de 2006 résumant la position de l’OMS sur le même sujet; elle renferme...
PATH
More than 300 million people who live in rural areas of the Mekong region are among the most at-risk for Japanese encephalitis (JE) infection due to changes in the Mekong region’s ecological...
Wendi Wu et al.
Introduction: Two types of Japanese encephalitis (JE) vaccines, inactivated JE vaccine (JE-I) and live-attenuated JE vaccine (JE-L), are available and used in China. In particular, one JE-L, produced...
Pushpa Ranjan Wijesinghe et al.
Background The performance of live attenuated Japanese Encephalitis SA 14-14-2 vaccine (CD-JEV) among children previously given inactivated mouse brain-derived JE vaccine (IMBV) is unknown. We...
PATH
• Determining the costs and requirements to finance a new JE vaccination program is the final, essential step in deciding to introduce JE vaccine into a national immunization program. • Before...
PATH
• WHO recommends that JE-endemic countries conduct a one-time JE vaccination campaign in the primary target population and then incorporate JE vaccine into the national immunization program (NIP)...
PATH
• Three JE vaccines have been prequalified by WHO as safe, effective, and acceptable for procurement by United Nations agencies. • Vaccination programs using any of the WHO-prequalified JE...
PATH
• Cost-effectiveness analysis is a useful way to compare the costs and benefits of introducing and maintaining JE vaccination with those of not introducing the vaccine. It is an important tool for...
PATH
Japanese encephalitis (JE), a viral infection that causes a type of “brain fever,” is transmitted to humans by mosquitoes. Because these mosquitoes usually live in areas with standing...
Grant L Campbell et al.
The global incidence of JE is unknown because the intensity and quality of JE surveillance and the availability of diagnostic laboratory testing vary throughout the world. Countries that have...
Pushpa Ranjan Wijesinghe et al.
To facilitate introduction of live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) into the National Immunization Programme of Sri Lanka, we evaluated the safety and immunogenicity of...
Jelinek T.
The mosquito-borne Japanese encephalitis virus causes an estimated 50,000 cases in Asia, accounting for at least 10,000 deaths and 15,000 cases of neuropsychiatric sequelae. IXIARO® (Intercell AG,...
World Health Organization
This article presents the World Health Organizations (WHO) recommendations on the use of Japanese Encephalitis (JE) vaccines excerpted from the WHO position paper on Japanese Encephalitis vaccines...
CDC
Three types of JE vaccine are used in national immunization programs. Inactivated mouse brain–derived JE vaccine has been available for >50 years, but has a multidose primary and booster schedule...